Research report
A research report is the sourced material a domain
dossier is synthesized from — generated on a plan and a cadence, one topic per file.
A report carries no confidence tags. Its bracketed markers say who might have
an incentive to shade a line; none of them says anyone checked it. To reach a score, a line has
to be drafted onto a candidate as unverified and pass the Verifier or the
Corroborator, like everything else.
Section clinical-evidence · Version 2026-09-01 · Cadence quarterly · Evidence class mixed · Sources 9 · Supersedes none
Domain: lower-extremity-lymphedema-compression-therapy · Scope: peer-reviewed and trial-registry sources reachable by this repo's connectors, WebSearch and WebFetch; a registered outcome with no results posted is a sponsor's intention, not a finding. Excludes CPT descriptors (AMA-licensed), MAUDE (no connector in this repo), and jurisdictions outside the US and EU.
Sourcing: the only head-to-head trial comparing a non-pneumatic to a pneumatic active compression device for lower-extremity lymphedema, and the professional-society position statement that leans on it, are both tied to the non-pneumatic device's own manufacturer as trial sponsor; the broader intermittent-pneumatic-compression evidence base rests on one independent systematic review of seven small RCTs
The domain dossier's §4/§5 already covers below-knee adjustable-strap wraps against flat-knit garments and short-stretch bandaging in detail; this pass targets a device class that dossier does not reach at all — pneumatic and non-pneumatic active compression devices, both of which carry FDA 510(k) clearances (unlike the exempt garment/wrap category already documented). A 2026 systematic review of randomized controlled trials found "moderate certainty" (GRADE) that intermittent pneumatic compression reduces lower-extremity lymphedema volume compared with standard care, across seven small trials [1]. The pivotal head-to-head comparison between a non-pneumatic active compression device (NPCD) and an advanced pneumatic compression device (APCD) — the TEAYS trial, a 9-site US crossover RCT — found the NPCD produced greater limb volume reduction, quality-of-life improvement, and adherence than the APCD [2], with a phlebolymphedema subgroup analysis reporting a similar pattern [3]. Both are tied to the NPCD manufacturer as trial sponsor [4], and a professional-society position statement built substantially on the same two trials advocates for the NPCD category specifically rather than surveying the field neutrally [5]. A lower-limb active-phase RCT not previously in this domain's file corroborates the dossier's existing finding that adjustable wraps and multilayer bandaging produce comparable volume reduction [6]. One independent scoping review records "rare cases of genital edema" as an adverse event of intermittent pneumatic compression, alongside more common transient skin irritation and paresthesia [7].
_Baseline (v1). No prior version; this establishes the starting point for future diffs._
Below-knee adjustable-strap wraps and flat-knit garments, both documented in the dossier's §5, are 510(k)-exempt. The two devices compared in this section's pivotal trial are not: the Koya Dayspring (a wearable NPCD) was cleared under K210885, decided 2021-04-23, with an Indications for Use statement covering "Lymphedema," "Primary lymphedema," "Post mastectomy edema," "Venous insufficiency," "Phlebolymphedema" and several other conditions, for use "in a clinic or home setting by medical professionals and patients who are under medical supervision" [8]. Tactile Medical's Flexitouch Plus System was cleared under K203178, decided 2020-12-20, with an Indications for Use statement covering the same list of conditions for "legs, arms, trunk, and chest" [9]. Both are class 1 registry facts, stated plainly with no marker. No FDA device recall was found for either firm in an openFDA query spanning 2016-09-03 to 2026-09-01 — a genuine null, not a search that wasn't run.
The TEAYS trial (NCT05507346, sponsor Koya Medical, Inc.) is a randomized, crossover, head-to-head study run at nine US sites in 2023, comparing the sponsor's own NPCD against "a commercially available APCD" not named in the retrieved abstract [4]. The published analysis covers 71 patients (108 affected limbs) with lower-extremity lymphedema, each using one device for 90 days, a 4-week washout, then the other device for 90 days: mean limb volume decrease was 369.9±68.19 mL for the NPCD versus 83.1±67.99 mL for the APCD (both p<.05); quality-of-life score improved 1.01±0.23 for the NPCD versus 0.17±0.18 (not significant) for the APCD; self-reported adherence was 81% versus 56% (p<.001); no device-related adverse events were reported [2] [single-source · manufacturer]. A subanalysis restricted to the 35 of 71 patients with phlebolymphedema (37% male, mean BMI 36.2±1.68, 54% bilateral) reported a similar pattern: mean limb volume reduction 424.49±100.9 mL (NPCD) versus 50.8±112.1 mL (APCD), p=.0085; quality of life improved 1.39±0.39 versus 0.18±0.29, p=.01; adherence 81% versus 49%, p≤.001 [3] [single-source · manufacturer]. The registry record for the parent trial reports 121 patients actually enrolled, larger than the 71 analyzed in the published paper; this pass did not reconcile that difference against the published methods.
A position statement endorsed by the American Venous Forum and the American Venous and Lymphatic Society reviews "two randomized controlled trials" in which the NPCD "demonstrated superior outcomes over advanced PCDs, including greater edema reduction, improved quality of life, and higher adherence rates," and concludes NPCD "should be considered" for inclusion "in future lymphedema treatment guidelines" [5] [single-source · manufacturer]. This is the closest thing located this pass to a guideline position on the pneumatic-versus-non-pneumatic comparison, but it is not a neutral treatment guideline: its cited comparative evidence is the same manufacturer-sponsored trial pair as [2] and [3], and its conclusion advocates for one manufacturer's device category specifically rather than surveying the field. No independent trial locating a non-pneumatic-versus-pneumatic comparison outside this sponsor's own program was found this pass.
Set against the single sponsor-tied trial above, a 2026 systematic review conducted "for a clinical practice guideline" identified seven RCTs meeting inclusion criteria for lower-extremity lymphedema in the maintenance phase (of 145 total lymphedema RCTs screened), average 54 patients per trial, mean age 55, 67% female. All seven showed statistically significant within-group limb-volume reduction from baseline to end of treatment; five of seven also showed a significant between-group difference. GRADE assessment found "moderate certainty that IPC reduces lower limb edema, volume, or circumference compared with standard care or no IPC," with Cochrane risk-of-bias assessment rating the studies "moderate methodological quality"; heterogeneity in arm composition prevented meta-analysis [1]. A separate scoping review of 49 studies (12 RCTs, 25 cohort studies, 12 experimental studies) on IPC broadly reported treatment pressures of 60-120 mmHg for lower limbs versus 25-60 mmHg for upper limbs, with higher pressures associated with greater lower-limb volume reduction, and recorded minor adverse events in six of the 49 studies, including "transient skin irritation, paresthesia, and rare cases of genital edema" [7] [single-source].
A 36-patient RCT (14 primary, 22 secondary lower-limb lymphedema, mean age 51.6±11.7 years, median disease duration 68 months) randomized patients to conventional short-stretch multilayer bandaging or an adjustable-strap velcro wrap (Circaid Reduction Kit) for a 3-week, 15-session active decongestive phase. Both arms achieved significant volume and ultrasonographic improvement sustained to one month; appearance, symptom and overall quality-of-life subscores improved only in the adjustable-wrap arm [6]. Read against the dossier's own §4 finding — a different, n=24 RCT (PMID 40015477) reporting noninferior volume reduction for adjustable wraps versus inelastic multilayer bandaging in the intensive phase — this is a second, independent, non-affiliated trial reaching the same substantive conclusion for lower-limb active-phase disease specifically, so it is stated here plainly: adjustable-strap wraps produce volume reduction in active-phase lower-limb lymphedema comparable to short-stretch multilayer bandaging, across two independent RCTs (n=24 and n=36).
[1] A systematic review of contemporary randomized controlled trials for treatment of lower extremity lymphedema by intermittent pneumatic compression devices — Journal of Vascular Surgery: Venous and Lymphatic Disorders (published 2026-07; accessed 2026-09-01). PMID 41997536 — https://pubmed.ncbi.nlm.nih.gov/41997536/ [peer-reviewed] [2] Results from a comparative study to evaluate the treatment effectiveness of a nonpneumatic compression device vs an advanced pneumatic compression device for lower extremity lymphedema swelling (TEAYS study) — Journal of Vascular Surgery: Venous and Lymphatic Disorders (published 2025-01; accessed 2026-09-01). PMID 39222789 — https://pubmed.ncbi.nlm.nih.gov/39222789/ [peer-reviewed] [3] Use of a Portable, Nonpneumatic Active Compression Device in Treatment of Phlebolymphedema: A TEAYS Subanalysis — Annals of Vascular Surgery (published 2026-07; accessed 2026-09-01). PMID 41850352 — https://pubmed.ncbi.nlm.nih.gov/41850352/ [peer-reviewed] [4] A Clinical Study to Evaluate the Effectiveness of a Novel Portable Non-Pneumatic Active Compression Device vs. an Advanced Pneumatic Compression Device for Treating Lower Extremity Lymphedema — ClinicalTrials.gov (last updated 2025-12-12; accessed 2026-09-01). NCT05507346 — https://clinicaltrials.gov/study/NCT05507346 [trial-registry] [5] Non-pneumatic compression and its clinical utility in management of lymphedema. A position statement endorsed by the American Venous Forum and the American Venous and Lymphatic Society — Journal of Vascular Surgery: Venous and Lymphatic Disorders (published 2026-03; accessed 2026-09-01). PMID 41271100 — https://pubmed.ncbi.nlm.nih.gov/41271100/ [guideline] [6] The Comparative Efficacy of Conventional Short-Stretch Multilayer Bandages and Velcro Adjustable Compression Wraps in Active Treatment Phase of Patients with Lower Limb Lymphedema — Lymphatic Research and Biology (published 2021-06; accessed 2026-09-01). PMID 33270499 — https://pubmed.ncbi.nlm.nih.gov/33270499/ [peer-reviewed] [7] Current Role of Pneumatic Compression Therapy in Lymphedema Care: A Scoping Review of Persistent Debates and New Applications — Lymphology (published 2024, month not given in the PubMed record; accessed 2026-09-01). PMID 39874051 — https://pubmed.ncbi.nlm.nih.gov/39874051/ [peer-reviewed] [8] FDA 510(k) summary, Koya Dayspring (Koya Medical, Inc.) — U.S. Food and Drug Administration (decided 2021-04-23; accessed 2026-09-01). K210885 — https://www.accessdata.fda.gov/cdrh_docs/pdf21/K210885.pdf [federal-registry] [9] FDA 510(k) summary, Flexitouch Plus System (Tactile Systems Technology, Inc., dba Tactile Medical) — U.S. Food and Drug Administration (decided 2020-12-20; accessed 2026-09-01). K203178 — https://www.accessdata.fda.gov/cdrh_docs/pdf20/K203178.pdf [federal-registry]
Well established: the two 510(k) clearances [8][9] are class-1 registry facts, stated plainly. The finding that adjustable-strap wraps achieve volume reduction comparable to short-stretch multilayer bandaging in active-phase lower-limb lymphedema is stated plainly on two independent, non-affiliated RCTs — [6] from this pass and PMID 40015477 already in the domain dossier's §4.
Thin: the entire pneumatic-versus-non-pneumatic comparative literature located this pass rests on one sponsor-tied trial program — [2] and [3] are, respectively, the primary analysis and a subgroup analysis of the same TEAYS trial ([4], sponsor Koya Medical, Inc., the NPCD's manufacturer) — marked [single-source · manufacturer] throughout. The position statement [5] draws its comparative evidence from the same trial pair and is marked the same way despite carrying two societies' endorsement. The independent systematic review [1] and scoping review [7] each rest on a single review located this pass, marked [single-source].
Rescoped from class 3: none in this report. Every proposition here is a registry fact (K-number, NCT record) or a published measured outcome; no question about what a clinician or patient would do was posed or answered.
Out of scope: CPT descriptors; MAUDE (no connector in this repo); any jurisdiction outside the US and EU. The ISL 2023 consensus document's full text, already recorded in the domain dossier's §4 as blocked by an access-control page on a prior pass, was not re-attempted this pass — effort went instead toward the pneumatic/non-pneumatic device class the dossier had not reached at all.
Not searched vs. not found: Not found — a literature search for "self-applied compression pressure accuracy home lymphedema wrap" was re-run this pass and returned zero PubMed records, reconfirming the domain dossier's own recorded gap on tension-reproducibility evidence for adjustable wraps. Not found — no independent (non-sponsor-affiliated) trial comparing a non-pneumatic to a pneumatic active compression device for lower-extremity lymphedema. Not searched — the discrepancy between the TEAYS registry's reported actual enrollment (121 patients, per [4]) and the 71 patients analyzed in the published paper [2] was noted but not reconciled against the trial's own methods section; the brand of the "commercially available APCD" used as the TEAYS comparator was not identified beyond the abstract's own description.
[inference] Describing the position statement [5] as advocacy for one device category rather than a neutral guideline follows directly from its own abstract's structure (its cited comparative evidence is exclusively the sponsor's two trials, and its conclusion recommends that category's inclusion in future guidelines) rather than from any external appraisal of the document; the full text was not retrieved this pass to check for a stated conflict-of-interest disclosure.
| Proposition | Evidence class | Resolvable identifier | Dossier section |
|---|---|---|---|
| A 2026 systematic review of seven RCTs found GRADE "moderate certainty" that intermittent pneumatic compression reduces lower-extremity lymphedema volume, edema or circumference compared with standard care or no IPC | 2 published | PMID 41997536 | 4 |
| In the TEAYS crossover RCT (n=71 patients, 108 limbs), a non-pneumatic active compression device produced significantly greater mean limb volume reduction than an advanced pneumatic compression device (369.9±68.19 mL vs 83.1±67.99 mL, both p<.05) | 2 published | PMID 39222789 | 4 |
| In a TEAYS subanalysis of 35 phlebolymphedema patients, the non-pneumatic device produced significantly greater limb volume reduction than the pneumatic comparator (424.49±100.9 mL vs 50.8±112.1 mL, p=.0085) | 2 published | PMID 41850352 | 4 |
| NCT05507346, sponsored by Koya Medical, Inc. (the non-pneumatic device's manufacturer), enrolled 121 patients and compares its own NPCD against an advanced pneumatic compression device for lower extremity lymphedema | 1 registry | NCT05507346 | 4 |
| The Koya Dayspring (K210885) and Tactile Medical Flexitouch Plus System (K203178) are both FDA 510(k)-cleared for lymphedema, including lower-extremity phlebolymphedema, distinct from the 510(k)-exempt compression garment/wrap category already documented in this domain | 1 registry | K210885; K203178 | 5 |
| A 36-patient RCT found volume and ultrasonographic improvement in both short-stretch bandaging and adjustable velcro-wrap arms during active-phase lower-limb lymphedema treatment, with quality-of-life subscores improving only in the adjustable-wrap arm | 2 published | PMID 33270499 | 4 |
| A scoping review of 49 IPC studies recorded minor adverse events in six studies, including transient skin irritation, paresthesia, and rare cases of genital edema | 2 published | PMID 39874051 | 4 |